Compare WHR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | ZLAB |
|---|---|---|
| Founded | 1911 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1994 | 2017 |
| Metric | WHR | ZLAB |
|---|---|---|
| Price | $35.95 | $25.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $74.33 | $49.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,253,000,000.00 | $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $3.48 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.58 | ★ 15.33 |
| 52 Week Low | $35.45 | $15.96 |
| 52 Week High | $94.82 | $34.72 |
| Indicator | WHR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.49 | 54.63 |
| Support Level | $35.84 | $24.81 |
| Resistance Level | $45.07 | $27.08 |
| Average True Range (ATR) | 1.70 | 0.78 |
| MACD | -0.45 | -0.29 |
| Stochastic Oscillator | 3.74 | 20.07 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.